Post-earnings recap
Reported
Thu, May 7, 2020
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Protagonist Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.63% decline in stock price. The lack of revenue data and forward guidance may raise concerns among investors about the company's short-term outlook. Management's cautious tone suggests they are navigating challenges while focusing on their clinical programs.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.72 | N/A | -12.50% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding the current market conditions. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs despite the challenges.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—